

21st MEET THE PROFESSOR

Advanced International Breast Cancer Course (AIBCC)

PADOVA,
SEPTEMBER 11th-12th, 2025

www.accmed.org



GYMNASIVM
MNIVM DISCIPLINA

PRINCIPE PASCHALI CICONIA
PRÆSID. IOANNE SVPERANTIO EQ. ET FEDERICO
REFORMATORIBVS IO. FRANCO PRIOLO DOCTORE, ZACHA
LEONARDO DONATO EQ. INSTAVRATVM ANNO M



Aims

Breast cancer research has been the frontrunner in many fields of cancer research: epidemiology, life-style and genetic risk factors, secondary prevention, conservative surgery, molecular classification, curative adjuvant therapies, neoadjuvant treatments, targeted agents, survival prolongation in advanced stages. Thanks to this knowledge, today many breast cancers can be prevented, most can be diagnosed at early stages and cured and the minority of patients at advanced stages can still enjoy a significant survival with a reasonable quality of life.

As a consequence of these major improvements, the bar of research and clinical excellence for breast cancer has raised even more.

New prognostic and predictive biomarkers are available, need to be validated and to be implemented in trial design and clinical practice. Risk-adapted surgery and radiation therapy allow for less and less invasive procedures. Multiple effective adjuvant therapies in the different molecular breast cancer subtypes, require a more precise definition of risk and predictivity of drug efficacy, to allow for a rational de-escalation or escalation of curative treatments. The impressive advances in the treatment of advanced breast cancers, envisage the possibility of cure with a multimodality approach for some patients and guarantee a prolonged survival for most of them with a rational sequencing of treatments.

The 21st AIBCC in Padova, will allow to sum up the most recent biological and clinical achievements and to allow an open and friendly discussion of clinical cases among key opinion leaders and participants.

Addressed to

Gynaecologists and obstetrics, medical oncologists, pathologists, radiologists, radiation oncologists, surgeons. Biologists, pharmacists, and nurses.

Programme

Thursday, September 11th

10.30 **Introduction to the Conference**

Pierfranco Conte, Valentina Guarneri, Philip Poortmans, Aleix Prat

SESSION I – EVOLVING KNOWLEDGE OF BREAST CANCER BIOLOGY: IMPLICATIONS FOR STAGING, PROGNOSIS AND PREDICTION

Chairpersons: Pierfranco Conte, Aleix Prat, Fabio Puglisi

11.00 **Gene expression tools in early-stage HR+/HER2- breast cancer: questioning the grey areas**

Alberto Zambelli

11.20 **The immune system and breast cancer: TNBC and beyond**

Maria Vittoria Dieci

11.40 **DNA NGS-based biomarkers to inform treatment sequence in advanced breast cancer**

Mafalda Oliveira

12.00 **Tackling the biological diversity in HER2-positive breast cancer: clinical implications**

Aleix Prat

12.20 **Discussion**

12.50 *Lunch*

SESSION II – GENETIC PREDISPOSITION TO BREAST CANCER

Chairpersons: Bettina Borisch, Fedro A. Peccatori

14.00 **Genetic testing beyond BRCA**

Teresa Ramon y Cajal

14.20 **Challenges in locoregional treatments:**

- **The surgeon's view** - Eleftherios Mamounas
- **The radiation oncologist's view** - Jacek Jassem
- **The patient's view point** - Bettina Borisch

15.00 **Systemic treatment options in patients with genetic predisposition with Early and Advanced disease**

Sandra Swain

15.30 **Discussion**

16.00 *Coffee break*

SESSION III – EARLY BREAST CANCER: NEOADJUVANT AND POST-NEOADJUVANT THERAPY

Chairpersons: Giuseppe Curigliano, Sibylle Loibl

16.20 **Modulation of neoadjuvant and post-neoadjuvant treatment in HER2+**
Sibylle Loibl

16.40 **Modulation of neoadjuvant and post-neoadjuvant treatment in TNBC**
Hope Rugo

17.00 **Neoadjuvant Treatment in HR+HER2-BC: why, when, which one**
Valentina Guarneri

17.20 **Response-guided radiotherapy after neoadjuvant treatments**
Angel Montero Luis

17.40 **Discussion**

18.00 **Ceremony for the presentation of the University of Padua Award for Advances in Breast Cancer 2025 (non CME session)**

18.45 **Adjourn and Cocktail**

Friday, September 12th

SESSION IV – EARLY BREAST CANCER

Chairpersons: Lucia del Mastro, Michelino De Laurentiis

9.00 **Enhancing efficacy of hormonal therapy in early breast cancer**
Stephen Johnston

9.20 **Adjuvant treatments for rare histologies: how to manage uncertainty**
Valentina Guarneri

9.40 **Life style intervention after breast cancer**
Claudio Vernieri

10.00 **Discussion**

10.30 *Coffee break*

11.00 **Clinical Multidisciplinary Shooting Session 1**
Early Breast Cancer

Panelists: Lucia Del Mastro, Michelino De Laurentiis, Hesham Ahmed Gaballah Elghazaly, Stephen Johnston, Eleftherios Mamounas, Philip Poortmans, Hope Rugo, Sandra Swain

12.30 *Lunch*

**SESSION V – METASTATIC BREAST CANCER: STATE OF ART
AND TRIALS LIKELY TO IMPACT IN THE FUTURE**

Chairpersons: Pierfranco Conte, Valentina Guarneri

13.30 **HR+ disease**
Laura Biganzoli

14.00 **HER2+ disease**
Giuseppe Curigliano

14.30 **Triple negative disease**
Hope Rugo

15.00 **Discussion**

15.20 **Clinical Multidisciplinary Shooting Session 2**
Advanced Breast Cancer

Panelists: Pierfranco Conte, Hesham Ahmed Gaballah Elghazaly, Jacek Jassem, Stephen Johnston, Eleftherios Mamounas, Sandra Swain, Hope Rugo

16.40 **Take home messages and adjourn**
Pierfranco Conte, Valentina Guarneri, Aleix Prat, Philip Poortmans

Directors

Pierfranco Conte

*Coordinator Molecular Tumor Board,
Rete Oncologica Veneta, Padova (I)
Scientific Director S. Camillo Hospital, IRCCS,
Venezia (I)*

Valentina Guarneri

*Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology
and Gastroenterology
University of Padova (I)*

Philip Poortmans

*Former president of ESTRO and of ECCO
Department of Radiation Oncology
Iridium Network
University of Antwerp
Wilrijk-Antwerp (B)*

Aleix Prat

*Clinic Barcelona Comprehensive Cancer Center
University of Barcelona
Barcelona (ES)*

Scientific Committee

Bettina Borisch

*Institute of Global Health
University of Geneva (CH)*

Maria Vittoria Dieci

*Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology
and Gastroenterology
University of Padova (I)*

Hesham Ahmed Gaballah Elghazaly

*Department of Clinical Oncology
and nuclear medicine
University of Ainshams
Cairo (EG)*

Jacek Jassem

*Department of Oncology and Radiotherapy
Medical University of Gdansk (PL)*

Stephen Johnston

*NIHR Biomedical Research Centre for Cancer
Royal Marsden NHS Foundation Trust
& Institute of Cancer Research
London (UK)*

Sibylle Loibl

*German Breast Group
University of Frankfurt (D)*

Eleftherios Mamounas

*Orlando Health Cancer Institute
Orlando (F)*

Fedro Alessandro Peccatori

*Department of Medical Oncology
European Institute of Oncology (IEO)
Milano (I)*

Sandra Swain M.

*Professor of Medicine,
Associate Dean Research Development
Georgetown University Medical Center
Washington (USA)*

Speakers & Chairpersons

Laura Biganzoli

*Breast Unit
Nuovo Ospedale Santo Stefano
Azienda USL Toscana Centro
Prato (I)*

Giuseppe Curigliano

*Department of Oncology
European Institute of Oncology
University of Milano (I)*

Michelino De Laurentiis

*Breast Unit
Istituto Nazionale Tumori IRCCS “
Fondazione G. Pascale”
Napoli (I)*

Lucia Del Mastro

*Division of Medical Oncology
IRCCS Ospedale Policlinico San Martino
Genova (I)*

Angel Montero Luis

*Radiation Oncology
Department of the Clara Campal Integral
Oncology Center (CIOCC)
University Hospital
Madrid*

Mafalda Oliveira

*Medical Department of the Vall d’Hebron
University
Hospital and Vall d’Hebron Institute
of Oncology (VHIO)
Barcellona (E)*

Fabio Puglisi

*Departamento of Medical Oncology
Centro di Riferimento Oncologico (CRO) - IRCCS
University of Udine
Aviano – PN (I)*

Hope Rugo

*Breast Oncology Clinical Trials Program
UCSF Carol Franc Buck Breast Care Center
San Francisco (USA)*

Teresa Ramon j Cajal

*Transactional Genomics and Targeted
Therapies in Solid Tumors
Clinic Barcelona
Barcelona (ES)*

Claudio Vernieri

*Division in Oncology
IRCCS Istituto Nazionale dei Tumori
Milano*

Alberto Zambelli

*Oncology Unit
ASST Papa Giovanni XXIII
Bergamo*

Award & Fellowships

UNIVERSITY OF PADUA AWARD FOR ADVANCES IN BREAST CANCER 2025

The Scientific Committee will select a young researcher working in Europe (≤ 40 years old, oncologists, radiation oncologists, pathologists). Candidates will be asked to submit a publication where they are the lead author, published in 2024–2025, along with a CV.

For application, the candidates have to send their CV and chosen publication 2024–2025, by July 30th, 2025 to info.bologna@accmed.org

The winner will be invited to present his study at the AIBCC (with travel and accommodation expenses covered).

FELLOWSHIPS

Some fellowship (for < 40) will be awarded including registration, 1 hotel night and travel organization. Those interested should send the registration form together with a short CV and a motivation letter within July 30th.

The organizing secretariat will confirm the award of the fellowship within August 5th and proceed with the organization of logistics.

UNDER 40

Free admission is available for some people “under 40”. Registration forms will be accepted on a first-come, first-served basis until spaces will be full. The Organization Secretariat will confirm the registration by email.



Un'azione sostenibile a favore della formazione

Iscrizione gratuita **UNDER 40** fino a esaurimento posti

CME

Based on the in force regulations approved by the CNFC, Accademia Nazionale di Medicina (provider n. 31) will assign to the activity CME (31- 453253): **12 CME points**.

Training objective: professional and technical content (knowledge and skills) specific to each profession, specialisation and highly specialised activity. Rare disease.

To obtain CME credits, participants must meet the following requirements:

1. Their declared profession/specialization must correspond to those accredited for CME;
2. They must attend at least 90% of the course;
3. They must complete the online meeting evaluation form;
4. They must pass the learning assessment test with at least 75% correct answers.

Only one attempt is allowed.

The learning assessment test and meeting evaluation form must be submitted within three days of the event.

Registration

Online registration at <https://fad.accmed.org/course/info.php?id=1768> before **September 5th**; the application will be completed only after the payment of the registration fee:

- **€ 120,00**
- **€ 80,00** for graduate students
- **€ 80,00** for AIOM members

CANCELLATION AND REFOUNDS

- In order to cancel please give advise with a written communication to Accademia Nazionale di Medicina within 10 days from the beginning. A 70% of the registration fee will be returned. Any cancellation after that deadline will not be reimbursed.

Official Language

The official language of the Meeting is English. No simultaneous translation will be provided.

Meeting Venue

Palazzo della Salute
Via San Francesco, 90
Padova

How to reach the venue:

The Center is located in the ZTL area.
We recommend the Interparking Italia – Via Trieste 50

Supported by unrestricted educational grants from

SILVER SPONSOR



BRONZE SPONSOR



CONTRIBUTORS



With the patronage of

INSTITUTIONS



PATROCINIO
REGIONE DEL VENETO



Comune di Padova



UNIVERSITÀ
DEGLI STUDI
DI PADOVA



REGIONE DEL VENETO
Azienda
Ospedale
Università
Padova



I.O.V.
ISTITUTO
ONCOLOGICO
VENETO
I.R.C.C.S.



DISCOG

SCIENTIFIC SOCIETIES



ASSOCIAZIONE
ITALIANA
ONCOLOGIA
MEDICA



CIPOMO

Collegio Italiano dei Primari Oncologi
Medici Ospedalieri



COLLEGIO
ONCOLOGI
MEDICI
UNIVERSITARI



RECOMMENDED BY
ESO
European School of Oncology



THE EUROPEAN SOCIETY
OF SURGICAL ONCOLOGY
Endorsed

ESTRO



fondazione
Periplo



Organizer

ACCADEMIA NAZIONALE DI MEDICINA

General Manager: Stefania Ledda
Via Martin Piaggio, 17/6
16122 Genova



Information and registration:
<http://meettheprofessor.accmed.org>
Ph. +39 051.6360080
info.bologna@accmed.org

Logistics and Technological Services

Forum Service
Via Martin Piaggio, 17/7
16122 Genova